Intricacies of the Molecular Machinery of Catecholamine Biosynthesis and Secretion by Chromaffin Cells of the Normal Adrenal Medulla and in Pheochromocytoma and Paraganglioma
暂无分享,去创建一个
L. Fishbein | I. Kema | T. Links | J. Lenders | G. Eisenhofer | M. Kerstens | Annika M A Berends | A. V. D. van der Horst-Schrivers
[1] C. Leemans,et al. Biochemically silent sympathetic Paraganglioma, Pheochromocytoma or Metastatic Disease in SDHD mutation carriers. , 2019, The Journal of clinical endocrinology and metabolism.
[2] A. Tabarin,et al. Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. , 2019, The Journal of clinical endocrinology and metabolism.
[3] M. Gilbert,et al. A Transgenic Mouse Model of Pacak–Zhuang Syndrome with An Epas1 Gain-of-Function Mutation , 2019, Cancers.
[4] C. Larsson,et al. Molecular Profiling of Pheochromocytoma and Abdominal Paraganglioma Stratified by the PASS Algorithm Reveals Chromogranin B as Associated With Histologic Prediction of Malignant Behavior , 2019, The American journal of surgical pathology.
[5] L. Eiden,et al. What's New in Endocrinology: The Chromaffin Cell , 2018, Front. Endocrinol..
[6] K. Pacak,et al. Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging , 2018, Front. Endocrinol..
[7] Min Zhao,et al. Octreotide reverses shock due to vasoactive intestinal peptide-secreting adrenal pheochromocytoma: A case report and review of literature , 2018, World journal of clinical cases.
[8] F. Beuschlein,et al. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. , 2018, Clinical chemistry.
[9] H. Sasano,et al. Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma , 2018, Endocrine Pathology.
[10] E. Korpershoek,et al. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (18F-FDOPA-PET) performed for imaging of neuroendocrine tumors. , 2018, European journal of endocrinology.
[11] Subha Arthur,et al. The Regulation and Function of the L-Type Amino Acid Transporter 1 (LAT1) in Cancer , 2018, International journal of molecular sciences.
[12] D. Aust,et al. Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma , 2018, Genetics in Medicine.
[13] T. Pons,et al. Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients , 2018, Genetics in Medicine.
[14] T. Links,et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. , 2018, European journal of internal medicine.
[15] E. Letouzé,et al. Germline Mutations in the Mitochondrial 2-Oxoglutarate/Malate Carrier SLC25A11 Gene Confer a Predisposition to Metastatic Paragangliomas. , 2018, Cancer research.
[16] V. Ambrosini,et al. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy? , 2018, International journal of molecular sciences.
[17] M. Wilkerson,et al. Chromaffin cell biology: inferences from The Cancer Genome Atlas , 2018, Cell and Tissue Research.
[18] K. Pacak,et al. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification , 2017, Endocrine reviews.
[19] C. Larsson,et al. Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention , 2017, JAMA oncology.
[20] W. Young,et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.
[21] W. Oyen,et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[22] A. Lam. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.
[23] Jenny Welander,et al. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas , 2017, Nature Reviews Endocrinology.
[24] B. Klink,et al. Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing. , 2017, The Clinical biochemist. Reviews.
[25] K. Pacak,et al. PRECISION MEDICINE: AN UPDATE ON GENOTYPE/BIOCHEMICAL PHENOTYPE RELATIONSHIPS IN PHEOCHROMOCYTOMA/PARAGANGLIOMA PATIENTS. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[26] Antonio L Amelio,et al. Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. , 2017, Cancer cell.
[27] Y. Kanai,et al. Structure-activity relationship of a novel series of inhibitors for cancer type transporter L-type amino acid transporter 1 (LAT1). , 2017, Journal of pharmacological sciences.
[28] Y. H. Lee,et al. Genetic Variations of Tyrosine Hydroxylase in the Pathogenesis of Hypertension , 2016, Electrolyte & blood pressure : E & BP.
[29] A. Lymperopoulos,et al. GPCRs of adrenal chromaffin cells & catecholamines: The plot thickens. , 2016, The international journal of biochemistry & cell biology.
[30] R. McCarty. Learning about stress: neural, endocrine and behavioral adaptations , 2016, Stress.
[31] J. Estévez-Herrera,et al. The intravesicular cocktail and its role in the regulation of exocytosis , 2016, Journal of neurochemistry.
[32] S. Chasserot-Golaz,et al. Annexin A2, an essential partner of the exocytotic process in chromaffin cells , 2016, Journal of neurochemistry.
[33] A. Fassina,et al. Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors , 2016, PloS one.
[34] A. Gimenez-Roqueplo,et al. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine , 2016, La Revue du praticien.
[35] Pang-Hu Zhou,et al. Plasma concentrations of adrenomedullin and atrial and brain natriuretic peptides in patients with adrenal pheochromocytoma. , 2015, Oncology letters.
[36] Lin Wang,et al. The role of L-type amino acid transporter 1 in human tumors. , 2015, Intractable & rare diseases research.
[37] A. Tischler,et al. Pathology of pheochromocytoma and paraganglioma , 2015 .
[38] A. Tischler,et al. 15 YEARS OF PARAGANGLIOMA: Pathology of pheochromocytoma and paraganglioma. , 2015, Endocrine-related cancer.
[39] M. Coleman,et al. OH, the Places You'll Go! Hydroxylation, Gene Expression, and Cancer. , 2015, Molecular cell.
[40] K. Abid,et al. Catecholamine Metabolism in Paraganglioma and Pheochromocytoma: Similar Tumors in Different Sites? , 2015, PloS one.
[41] David B. Wilson,et al. Adrenocortical Zonation, Renewal, and Remodeling , 2015, Front. Endocrinol..
[42] Q. Schwarz,et al. Sympathoadrenal neural crest cells: The known, unknown and forgotten? , 2015, Development, growth & differentiation.
[43] Tank Aw,et al. Peripheral and central effects of circulating catecholamines. , 2014 .
[44] F. Beuschlein,et al. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma. , 2014, European journal of endocrinology.
[45] K. Pacak,et al. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC‐associated factor X , 2014, International journal of cancer.
[46] Yingyong Hou,et al. A rare case of watery diarrhea, hypokalemia and achlorhydria syndrome caused by pheochromocytoma , 2014, BMC Cancer.
[47] F. Beuschlein,et al. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. , 2014, The Journal of clinical endocrinology and metabolism.
[48] S. Asa,et al. Malignant pheochromocytoma secreting vasoactive intestinal peptide and response to sunitinib: a case report and literature review. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[49] S. Ito,et al. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. , 2014, Endocrine-related cancer.
[50] P. Rustin,et al. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.
[51] K. Pacak,et al. Clinical utility of chromogranin A in SDHx‐related paragangliomas , 2014, European journal of clinical investigation.
[52] J. Lenders,et al. Pathophysiology and diagnosis of disorders of the adrenal medulla: focus on pheochromocytoma. , 2014, Comprehensive Physiology.
[53] M. Montero-Hadjadje,et al. Characterization and Plasma Measurement of the WE-14 Peptide in Patients with Pheochromocytoma , 2014, PloS one.
[54] P. Hellman,et al. Integrative Genetic Characterization and Phenotype Correlations in Pheochromocytoma and Paraganglioma Tumours , 2014, PloS one.
[55] P. Dahia. Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.
[56] R. Borges,et al. The role of chromogranins in the secretory pathway , 2013, Biomolecular concepts.
[57] Y. Loh,et al. Carboxypeptidase E promotes cancer cell survival, but inhibits migration and invasion. , 2013, Cancer letters.
[58] Laurence Amar,et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.
[59] P. Hellman,et al. Somatic mutations in H-RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. , 2013, The Journal of clinical endocrinology and metabolism.
[60] S. Roman,et al. Malignant pheochromocytoma and paraganglioma: A population level analysis of long‐term survival over two decades , 2013, Journal of surgical oncology.
[61] D. Fraker,et al. Inherited Mutations in Pheochromocytoma and Paraganglioma: Why All Patients Should Be Offered Genetic Testing , 2013, Annals of Surgical Oncology.
[62] F. Beuschlein,et al. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma , 2013, Annals of clinical biochemistry.
[63] H. Timmers,et al. Is the excess cardiovascular morbidity in pheochromocytoma related to blood pressure or to catecholamines? , 2013, The Journal of clinical endocrinology and metabolism.
[64] J. Lenders,et al. Mortality Associated with Phaeochromocytoma , 2013, Hormone and Metabolic Research.
[65] S. Bornstein,et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. , 2012, European journal of cancer.
[66] Hui Yang,et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.
[67] L. Eiden,et al. Is PACAP the Major Neurotransmitter for Stress Transduction at the Adrenomedullary Synapse? , 2012, Journal of Molecular Neuroscience.
[68] N. Seidah,et al. Differential expression and processing of secretogranin II in relation to the status of pheochromocytoma: implications for the production of the tumoral marker EM66. , 2012, Journal of molecular endocrinology.
[69] M. Urioste,et al. MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma , 2012, Clinical Cancer Research.
[70] Mubarak Shah,et al. Distinctive Left-Sided Distribution of Adrenergic-Derived Cells in the Adult Mouse Heart , 2011, PloS one.
[71] A. Vénisse,et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. , 2011, Human molecular genetics.
[72] K. Wimalasena. Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry , 2011, Medicinal research reviews.
[73] S. Daubner,et al. Tyrosine hydroxylase and regulation of dopamine synthesis. , 2011, Archives of biochemistry and biophysics.
[74] K. Pacak. Phaeochromocytoma: a catecholamine and oxidative stress disorder. , 2011, Endocrine regulations.
[75] M. Fraenkel,et al. Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center , 2011, Endocrine.
[76] Lei Feng,et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.
[77] L. Hofbauer,et al. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. , 2011, Clinical chemistry.
[78] A. Mcnicol,et al. Update on tumours of the adrenal cortex, phaeochromocytoma and extra‐adrenal paraganglioma , 2011, Histopathology.
[79] S. Bornstein,et al. Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. , 2010, Endocrine-related cancer.
[80] Agnieszka Maliszewska,et al. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. , 2010, Molecular endocrinology.
[81] Vivian Hook,et al. Unique biological function of cathepsin L in secretory vesicles for biosynthesis of neuropeptides , 2010, Neuropeptides.
[82] Y. Anouar,et al. Expression of Trophic Peptides and Their Receptors in Chromaffin Cells and Pheochromocytoma , 2010, Cellular and Molecular Neurobiology.
[83] Y. Loh,et al. Carboxypeptidase E: Elevated Expression Correlated with Tumor Growth and Metastasis in Pheochromocytomas and Other Cancers , 2010, Cellular and Molecular Neurobiology.
[84] Nitin Gupta,et al. Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing. , 2010, Journal of proteome research.
[85] J. Bertherat,et al. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival. , 2010, Endocrine-related cancer.
[86] Y. Bailly,et al. S100A10‐Mediated Translocation of Annexin‐A2 to SNARE Proteins in Adrenergic Chromaffin Cells Undergoing Exocytosis , 2010, Traffic.
[87] D. O'Connor,et al. Human Tyrosine Hydroxylase Natural Allelic Variation: Influence on Autonomic Function and Hypertension , 2010, Cellular and Molecular Neurobiology.
[88] D. O'Connor,et al. Catestatin: A multifunctional peptide from chromogranin A , 2010, Regulatory Peptides.
[89] A. Tischler,et al. Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla , 2010, Cell and Tissue Research.
[90] P. Bénit,et al. The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas , 2009, PloS one.
[91] E. D. de Vries,et al. Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results. , 2009, Critical reviews in oncology/hematology.
[92] A. Vénisse,et al. The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas. , 2009, The Journal of clinical endocrinology and metabolism.
[93] N. Guérineau,et al. Revisiting the Stimulus-Secretion Coupling in the Adrenal Medulla: Role of Gap Junction-Mediated Intercellular Communication , 2009, Molecular Neurobiology.
[94] A. Tischler,et al. Observer Variation in the Application of the Pheochromocytoma of the Adrenal Gland Scaled Score , 2009, The American journal of surgical pathology.
[95] E. Crivellato,et al. The Chromaffin Vesicle: Advances in Understanding the Composition of a Versatile, Multifunctional Secretory Organelle , 2008, Anatomical record.
[96] M. Merino,et al. Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. , 2008, The Journal of clinical endocrinology and metabolism.
[97] A. Elkahloun,et al. Differential expression of the regulated catecholamine secretory pathway in different hereditary forms of pheochromocytoma. , 2008, American journal of physiology. Endocrinology and metabolism.
[98] Shin‐Rong Hwang,et al. Endopin Serpin Protease Inhibitors Localize with Neuropeptides in Secretory Vesicles and Neuroendocrine Tissues , 2008, Neuroendocrinology.
[99] E. Pellizzari,et al. Possible autocrine enkephalin regulation of catecholamine release in human pheochromocytoma cells. , 2008, Life sciences.
[100] Y. Imai,et al. Expression of adrenomedullin 2/intermedin in human adrenal tumors and attached non-neoplastic adrenal tissues. , 2008, The Journal of endocrinology.
[101] M. Stridsberg,et al. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours , 2008, Regulatory Peptides.
[102] Jae Joon Lee,et al. Effects of Anonaine on Dopamine Biosynthesis and l-DOPA-Induced Cytotoxicity in PC12 Cells , 2008, Molecules.
[103] H. Vaudry,et al. Role of PACAP in the physiology and pathology of the sympathoadrenal system , 2008, Frontiers in Neuroendocrinology.
[104] S. Gasman,et al. Cytoskeletal control of vesicle transport and exocytosis in chromaffin cells , 2007, Acta physiologica.
[105] F. Sala,et al. Nicotinic acetylcholine receptors of adrenal chromaffin cells , 2007, Acta physiologica.
[106] E. Baudin,et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.
[107] L. Bottarelli,et al. Peptide products of the neurotrophin-inducible gene vgf are produced in human neuroendocrine cells from early development and increase in hyperplasia and neoplasia. , 2007, The Journal of clinical endocrinology and metabolism.
[108] Deric M. Park,et al. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. , 2007, Endocrine-related cancer.
[109] R. Worrell,et al. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. , 2007, The Journal of endocrinology.
[110] H. Vaudry,et al. Involvement of multiple signaling pathways in PACAP-induced EM66 secretion from chromaffin cells , 2006, Regulatory Peptides.
[111] J. García-Sancho,et al. Calcium signaling and exocytosis in adrenal chromaffin cells. , 2006, Physiological reviews.
[112] N. Seidah,et al. Expression and Processing of the Neuroendocrine Protein Secretogranin II in Benign and Malignant Pheochromocytomas , 2006, Annals of the New York Academy of Sciences.
[113] W. Scherbaum,et al. Expression of Connexins in Chromaffin Cells of Normal Human Adrenals and in Benign and Malignant Pheochromocytomas , 2006, Annals of the New York Academy of Sciences.
[114] C. Cavadas,et al. Deletion of the neuropeptide Y (NPY) Y1 receptor gene reveals a regulatory role of NPY on catecholamine synthesis and secretion , 2006, Proceedings of the National Academy of Sciences.
[115] S. Richard,et al. Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[116] R. Worrell,et al. Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. , 2005, European journal of endocrinology.
[117] R. Kirchmair,et al. Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. , 2005, Current protein & peptide science.
[118] Sandro Santagata,et al. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.
[119] L. Dubois,et al. Dopamine-secreting Pheochromocytomas: In Search of a Syndrome , 2005, World Journal of Surgery.
[120] Jason U Tilan,et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. , 2005, Cancer research.
[121] A. Harris,et al. HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. , 2005, Experimental cell research.
[122] T. Fujita,et al. Adrenomedullin and its related peptide. , 2005, Endocrine journal.
[123] P. Munson,et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. , 2004, Endocrine-related cancer.
[124] A. Tischler,et al. Neuroendocrine Secretory Protein-55 (NESP-55) Expression Discriminates Pancreatic Endocrine Tumors and Pheochromocytomas From Gastrointestinal and Pulmonary Carcinoids , 2004, The American journal of surgical pathology.
[125] S. Bornstein,et al. Vitamin C Is an Important Cofactor for Both Adrenal Cortex and Adrenal Medulla , 2004, Endocrine Research.
[126] D. Aunis,et al. Innate immunity: involvement of new neuropeptides. , 2003, Trends in microbiology.
[127] S. Yoo,et al. Chromogranin B-induced Secretory Granule Biogenesis , 2003, Journal of Biological Chemistry.
[128] C. Cohen,et al. Galanin Immunoreactivity in Paragangliomas but Not in Carcinoid Tumors , 2003, Applied immunohistochemistry & molecular morphology : AIMM.
[129] M. Bogyo,et al. Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[130] H. Vaudry,et al. Identification of the secretogranin II-derived peptide EM66 in pheochromocytomas as a potential marker for discriminating benign versus malignant tumors. , 2003, The Journal of clinical endocrinology and metabolism.
[131] O. Nilsson,et al. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids , 2003, British Journal of Cancer.
[132] K. Pacak,et al. Pheochromocytoma as an Endocrine Emergency , 2003, Reviews in Endocrine and Metabolic Disorders.
[133] F. Cuttitta,et al. Adrenomedullin and cancer , 2003, Regulatory Peptides.
[134] Alan Morgan,et al. Secretory granule exocytosis. , 2003, Physiological reviews.
[135] H. Hollema,et al. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. , 2003, Clinical chemistry.
[136] S. Salton. Neurotrophins, growth-factor-regulated genes and the control of energy balance. , 2003, The Mount Sinai journal of medicine, New York.
[137] J. Trifaró. Molecular Biology of the Chromaffin Cell , 2002, Annals of the New York Academy of Sciences.
[138] T. Tai,et al. Cholinergic and Peptidergic Regulation of Phenylethanolamine N‐Methyltransferase Gene Expression , 2002, Annals of the New York Academy of Sciences.
[139] Y. Sugisaki,et al. Immunohistochemical, biochemical and immunoelectron microscopic analysis of antigenic proteins on neuroendocrine cell tumors using monoclonal antibody HISL-19. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[140] H. Bonjer,et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. , 2002, European journal of endocrinology.
[141] J. Haycock,et al. Lack of regulation of aromatic l‐amino acid decarboxylase in intact bovine chromaffin cells , 2002, Journal of neurochemistry.
[142] L. Thompson. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.
[143] T. Flatmark,et al. Ubiquitination of soluble and membrane-bound tyrosine hydroxylase and degradation of the soluble form. , 2002, European journal of biochemistry.
[144] C. Cavadas,et al. NPY regulates catecholamine secretion from human adrenal chromaffin cells. , 2001, The Journal of clinical endocrinology and metabolism.
[145] S. Bornstein,et al. The importance of adrenocortical glucocorticoids for adrenomedullary and physiological response to stress: a study in isolated glucocorticoid deficiency. , 2001, The Journal of clinical endocrinology and metabolism.
[146] K. Unsicker,et al. Reduction of endogenous TGF-β does not affect phenotypic development of sympathoadrenal progenitors into adrenal chromaffin cells , 2001, Mechanisms of Development.
[147] Y. Kanai,et al. Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. , 2001, Biochimica et biophysica acta.
[148] Y. Loh,et al. Chromogranin A, an “On/Off” Switch Controlling Dense-Core Secretory Granule Biogenesis , 2001, Cell.
[149] K. Pacak,et al. Understanding Catecholamine Metabolism as a Guide to the Biochemical Diagnosis of Pheochromocytoma , 2001, Reviews in Endocrine and Metabolic Disorders.
[150] G. Eisenhofer. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. , 2001, Pharmacology & therapeutics.
[151] H. Vaudry,et al. Pituitary adenylate cyclase-activating polypeptide stimulates secretoneurin release and secretogranin II gene transcription in bovine adrenochromaffin cells through multiple signaling pathways and increased binding of pre-existing activator protein-1-like transcription factors. , 2001, Molecular pharmacology.
[152] D. Moura,et al. Vascular adrenoceptors: an update. , 2001, Pharmacological reviews.
[153] A. Vortmeyer,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes , 2022 .
[154] R. Kvetňanský,et al. Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events , 2001, Trends in Neurosciences.
[155] G. Chrousos,et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. , 2000, The New England journal of medicine.
[156] D. O'Connor,et al. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion. , 2000, The Journal of clinical investigation.
[157] Chi-Wei Lee,et al. Cardiovascular manifestations of pheochromocytoma. , 2000, The American journal of emergency medicine.
[158] C. Wiedermann. Secretoneurin: a functional neuropeptide in health and disease , 2000, Peptides.
[159] R. Possenti,et al. VGF: A Novel Role for This Neuronal and Neuroendocrine Polypeptide in the Regulation of Energy Balance , 2000, Frontiers in Neuroendocrinology.
[160] D. Aunis,et al. Antibacterial and Antifungal Activities of Vasostatin-1, the N-terminal Fragment of Chromogranin A* , 2000, The Journal of Biological Chemistry.
[161] P. Corvol,et al. Cloning and expression pattern of EPAS1 in the chicken embryo , 1999, FEBS letters.
[162] D. Aunis,et al. Physiological aspects of exocytosis in chromaffin cells of the adrenal medulla. , 1999, Acta physiologica Scandinavica.
[163] R. Hammer,et al. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. , 1998, Genes & development.
[164] S. Her,et al. Phenylethanolamine N-methyltransferase gene expression: synergistic activation by Egr-1, AP-2 and the glucocorticoid receptor. , 1998, Brain research. Molecular brain research.
[165] H. Lehnert. Regulation of catecholamine synthesizing enzyme gene expression in human pheochromocytoma. , 1998, European journal of endocrinology.
[166] R. Burgoyne,et al. Analysis of regulated exocytosis in adrenal chromaffin cells: insights into NSF/SNAP/SNARE function , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.
[167] K. Takekoshi,et al. Expression of mRNA coding for four catecholamine-synthesizing enzymes in human adrenal pheochromocytomas. , 1998, European journal of endocrinology.
[168] J. Henry,et al. The vesiicular monoamine transporter: from chromaffin granule to brain , 1998, Neurochemistry International.
[169] R. Picart,et al. Aminopeptidase B: a processing enzyme secreted and associated with the plasma membrane of rat pheochromocytoma (PC12) cells. , 1998, Journal of cell science.
[170] N. Seidah,et al. Proteolytic Processing of Chromogranin B and Secretogranin II by Prohormone Convertases , 1998, Journal of neurochemistry.
[171] D. O'Connor,et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. , 1997, The Journal of clinical investigation.
[172] S. Mahata,et al. Tissue Plasminogen Activator (t-PA) Is Targeted to the Regulated Secretory Pathway , 1997, The Journal of Biological Chemistry.
[173] G. Mazzocchi,et al. Adrenomedullin stimulates steroid secretion by the isolated perfused rat adrenal gland in situ: Comparison with calcitonin gene-related peptide effects , 1996, Peptides.
[174] D. Aunis,et al. Antibacterial Activity of Glycosylated and Phosphorylated Chromogranin A-derived Peptide 173-194 from Bovine Adrenal Medullary Chromaffin Granules* , 1996, The Journal of Biological Chemistry.
[175] K. Wimalasena,et al. Reduction of Dopamine β-Monooxygenase , 1996, The Journal of Biological Chemistry.
[176] Y. Chen,et al. Regulation of tyrosine hydroxylase gene expression by the m1 muscarinic acetylcholine receptor in rat pheochromocytoma cells. , 1996, Brain research. Molecular brain research.
[177] E. Carbone,et al. The mechanism of calcium channel facilitation in bovine chromaffin cells. , 1996, The Journal of physiology.
[178] K. Unsicker,et al. Growth factors in chromaffin cells , 1996, Progress in Neurobiology.
[179] M. Schiller,et al. Chromaffin granule aspartic proteinase processes recombinant proopiomelanocortin (POMC). , 1995, Biochemical and biophysical research communications.
[180] I. Kopin,et al. Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines. , 1995, The Journal of clinical endocrinology and metabolism.
[181] M. Zhu,et al. Aromatic L-amino acid decarboxylase: biological characterization and functional role. , 1995, General pharmacology.
[182] B. Kennedy,et al. Nonadrenal epinephrine-forming enzymes in humans. Characteristics, distribution, regulation, and relationship to epinephrine levels. , 1995, The Journal of clinical investigation.
[183] H. Schlüter,et al. Coenzyme A glutathione disulfide. A potent vasoconstrictor derived from the adrenal gland. , 1995, Circulation research.
[184] M Linial,et al. Vesicular neurotransmitter transporters: from bacteria to humans. , 1995, Physiological reviews.
[185] D. Aunis,et al. Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614-626 with antibacterial activity. , 1995, European journal of biochemistry.
[186] A. De Léan,et al. Natriuretic Peptides Inhibit Nicotine‐Induced Whole‐Cell Currents and Catecholamine Secretion in Bovine Chromaffin Cells: Evidence for the Involvement of the Atrial Natriuretic Factor R2 Receptors , 1995, Journal of neurochemistry.
[187] T. Koshikawa,et al. Discrepancy between PNMT presence and relative lack of adrenaline production in extra‐adrenal pheochromocytoma , 1994, Journal of surgical oncology.
[188] F. Supek,et al. A novel accessory subunit for vacuolar H(+)-ATPase from chromaffin granules. , 1994, The Journal of biological chemistry.
[189] R. Angeletti,et al. Inhibition of parathyroid hormone secretion by amino-terminal chromogranin peptides. , 1994, Endocrinology.
[190] I. Macara,et al. Evidence for the involvement of Rab3A in Ca(2+)-dependent exocytosis from adrenal chromaffin cells. , 1994, The Journal of biological chemistry.
[191] H. Funahashi,et al. Tyrosine hydroxylase indicates cell differentiation of catecholamine biosynthesis in neuroendocrine tumors , 1994, Journal of endocrinological investigation.
[192] R. Burgoyne,et al. Exocytosis in adrenal chromaffin cells. , 1993, Journal of anatomy.
[193] Xin-Min Li,et al. NSD-1015 alters the gene expression of aromaticl-amino acid decarboxylase in rat PC12 pheochromocytoma cells , 1993, Neurochemical Research.
[194] D. L. Wong,et al. Glucocorticoid regulation of phenylethanolamine N‐methyltransferase in vivo , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[195] K. Helle,et al. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels , 1992, Regulatory Peptides.
[196] K. Nakao,et al. Characterization of Natriuretic Peptide Receptors in Cultured Cells , 1992, Hypertension.
[197] G. Chejfec,et al. Plasma calcitonin gene-related peptide and atrial natriuretic peptide levels during resection of pheochromocytoma. , 1991, Surgery.
[198] M. Sporn,et al. Localization and actions of transforming growth factor-beta s in the embryonic nervous system. , 1991, Development.
[199] M. Wolf,et al. Effect of Aging on Tyrosine Hydroxylase Protein Content and the Relative Number of Dopamine Nerve Terminals in Human Caudate , 1991, Journal of neurochemistry.
[200] D. O'Connor,et al. Chromogranin A Storage and Secretion: Sensitivity and Specificity for the Diagnosis of Pheochromocytoma , 1991, Medicine.
[201] B. Livett,et al. Substance P has biphasic effects on catecholamine secretion evoked by electrical stimulation of perfused rat adrenal glands in vitro. , 1990, Journal of the autonomic nervous system.
[202] T. Hökfelt,et al. The glucocorticoid receptor in the adrenal gland is localized in the cytoplasm of adrenaline cells. , 1989, Acta physiologica Scandinavica.
[203] M. Israel,et al. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[204] G. Painter,et al. 31P nuclear magnetic resonance study of the metabolic pools of adenosine triphosphate in cultured bovine adrenal medullary chromaffin cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[205] E. Grouzmann,et al. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. , 1989, The Journal of clinical endocrinology and metabolism.
[206] T. Nakada,et al. Catecholamine metabolism in pheochromocytoma and normal adrenal medullae. , 1988, The Journal of urology.
[207] N. Seidah,et al. Identification and localization of 7B2 protein in human, porcine, and rat thyroid gland and in human medullary carcinoma. , 1988, Endocrinology.
[208] H. Nawata,et al. Plasma 7B2 (a novel pituitary protein) immunoreactivity concentrations in patients with various endocrine disorders. , 1988, Endocrinologia japonica.
[209] S. Simasko,et al. Effects of Substance P on Nicotinic Acetylcholine Receptor Function in PC 12 Cells , 1987, Journal of neurochemistry.
[210] T. Adrian,et al. Localization and molecular forms of galanin in human adrenals: elevated levels in pheochromocytomas. , 1986, The Journal of clinical endocrinology and metabolism.
[211] K. Hecht,et al. Relationship of Substance P to Catecholamines, Stress, and Hypertension , 1986, Journal of cardiovascular pharmacology.
[212] A. Vinik,et al. Plasma gut hormone levels in 37 patients with pheochromocytomas , 1986, World Journal of Surgery.
[213] D. Apps,et al. The molecular function of adrenal chromaffin granules: Established facts and unresolved topics , 1986, Neuroscience.
[214] D. O'Connor,et al. Secretion of chromogranin A by peptide-producing endocrine neoplasms. , 1986, The New England journal of medicine.
[215] G. Chejfec,et al. Bombesin in human neuroendocrine (NE) neoplasms , 1985, Peptides.
[216] D. Bostwick,et al. Gastrin releasing peptide in human neuroendocrine tumours , 1985, The Journal of pathology.
[217] P. Palatini. Fumarate is the cause of the apparent ping-pong kinetics of dopamine beta-hydroxylase. , 1985, Biochemistry international.
[218] B. Livett. Adrenal medullary chromaffin cells in vitro. , 1984, Physiological reviews.
[219] A. Tischler,et al. Production of "ectopic" vasoactive intestinal peptide-like and neurotensin-like immunoreactivity in human pheochromocytoma cell cultures , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[220] K. Nakao,et al. Plasma methionine-enkephalin and leucine-enkephalin in normal subjects and patients with pheochromocytoma. , 1983, The Journal of clinical endocrinology and metabolism.
[221] Harvey J. Motulsky,et al. Adrenergic receptors in man , 1982 .
[222] A. Tischler,et al. Content and release of neurotensin in PC12 pheochromocytoma cell cultures: modulation by dexamethasone and nerve growth factor , 1982, Regulatory Peptides.
[223] S. Wells,et al. The relationship between enzyme activity and the catecholamine content and secretion of pheochromocytomas. , 1979, The Journal of clinical endocrinology and metabolism.
[224] P. Yu. PhenylethanolamineN-methyltransferase from the brain and adrenal medulla of the rat , 1978 .
[225] W. Louis,et al. Abnormalities in enzymes involved in catecholamine synthesis and catabolism in phaeochromocytoma. , 1977, Clinical science and molecular medicine.
[226] R. Weinshilboum,et al. Serum Dopamine‐Beta‐Hydroxylase Activity , 1971, Circulation research.
[227] S. Kaufman,et al. 3,4-dihydroxyphenylethylamine beta-hydroxylase. Physical properties, copper content, and role of copper in the catalytic acttivity. , 1965, The Journal of biological chemistry.
[228] S. Udenfriend,et al. TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.
[229] S. Kaufman,et al. The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. , 1960, The Journal of biological chemistry.
[230] A. M. Cárdenas,et al. How does the stimulus define exocytosis in adrenal chromaffin cells? , 2017, Pflügers Archiv - European Journal of Physiology.
[231] A William Tank,et al. Peripheral and central effects of circulating catecholamines. , 2015, Comprehensive Physiology.
[232] U. Shankavaram,et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia , 2014, Journal of Molecular Medicine.
[233] A. Munnich,et al. Kinetic analyses guide the therapeutic decision in a novel form of moderate aromatic Acid decarboxylase deficiency. , 2012, JIMD reports.
[234] S. Bornstein,et al. Update on the corticomedullary interaction in the adrenal gland. , 2011, Endocrine development.
[235] S. Bornstein,et al. Cortical-chromaffin cell interactions in the adrenal gland , 2005, Endocrine pathology.
[236] Eyal Gottlieb,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[237] H. Nagura,et al. Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma , 2005, Virchows Archiv A.
[238] G. Nussdorfer,et al. Neuropeptide-Y and Y-receptors in the autocrine-paracrine regulation of adrenal gland under physiological and pathophysiological conditions (Review). , 2005, International journal of molecular medicine.
[239] Andrew L. Kung,et al. A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas , 2005 .
[240] David G. Watson,et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.
[241] R. DeLellis. Pathology and genetics of tumours of endocrine organs , 2004 .
[242] J. Polak,et al. Multiple peptide production and presence of general neuroendocrine markers detected in 12 cases of human phaeochromocytoma and in mammalian adrenal glands , 2004, Virchows Archiv A.
[243] D. L. Wong. Why is the adrenal adrenergic? , 2003, Endocrine pathology.
[244] P. Tessari,et al. The metabolic conversion of phenylalanine into tyrosine in the human kidney: does it have nutritional implications in renal patients? , 2002, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.
[245] M. Stridsberg,et al. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma. , 1997, European journal of endocrinology.
[246] T Nagatsu,et al. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. , 1995, Essays in biochemistry.
[247] W. Scherbaum,et al. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. , 1994, The Journal of clinical endocrinology and metabolism.
[248] S. Steinberg,et al. Decreased expression of neuropeptides in malignant paragangliomas: an immunohistochemical study. , 1988, Human pathology.
[249] S. Carmichael. The adrenal chromaffin vesicle: an historical perspective. , 1983, Journal of the autonomic nervous system.
[250] H J Motulsky,et al. Adrenergic receptors in man: direct identification, physiologic regulation, and clinical alterations. , 1982, The New England journal of medicine.
[251] J. Feldman. Phenylethanolamine-N-methyltransferase activity determines the epinephrine concentration of pheochromocytomas. , 1981, Research communications in chemical pathology and pharmacology.
[252] N. Hillarp,et al. Evidence of adrenaline and noradrenaline in separate adrenal medullary cells. , 1953, Acta physiologica Scandinavica.